Latest news and press releases about Phio Pharmaceuticals Corp. (PHIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Price
| Price | $1.00 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | 0.03 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -87.41% |
| Return on Invested Capital | -100.51% |
| Return on Assets | -90.19% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · APRE · APVO · BCDA · CELZ · GLTO · INAB
Explore sector: Healthcare · Biotechnology
More sections of PHIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks